|
Tue, 03/18/2025 - 21:51 |
Chugai Launches LUNSUMIO for Intravenous Infusion, a Bispecific Antibody for Relapsed or Refractory Follicular Lymphoma in Japan |
Chugai |
|
Sat, 02/08/2025 - 13:51 |
Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma |
Merck |
|
Fri, 01/17/2025 - 05:27 |
Chugai Wins the MHLW Ministers Award at the Seventh Japan Medical Research and Development Grand Prize for the Discovery of an ALK-Positive Lung Cancer Treatment Alecensa |
Chugai |
|
Thu, 12/12/2024 - 01:11 |
Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-Cell Lymphomas? New Insights at ASH |
Roswell Park Ca... |
|
Tue, 08/06/2024 - 07:59 |
Moffitt Consortium Study Answers Questions About Long-Term Survivorship Following CAR T Treatment |
Moffitt |
|
Wed, 07/10/2024 - 23:16 |
Study highlights the importance of infection prevention after CAR T-cell therapy |
Dana Farber |
|
Fri, 06/07/2024 - 13:46 |
Epstein-Barr Virus and brain cross-reactivity: possible mechanism for Multiple Sclerosis |
University of B... |
|
Fri, 05/10/2024 - 22:20 |
Leukemia & Lymphoma Society supports trials in cell-based immunotherapies, cancer vaccines |
Washington Univ... |
|
Thu, 02/01/2024 - 22:23 |
Simple Blood Protein Tests Predict Which Lymphoma Patients Are Most Likely to Have Poor CAR T Outcomes |
Roswell Park Ca... |
|
Mon, 12/19/2022 - 05:36 |
Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis |
Soligenix |
|
Mon, 12/12/2022 - 09:17 |
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022 |
Oxis Biotech |
|
Sun, 12/11/2022 - 10:16 |
CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial |
Dana Farber |
|
Sat, 12/10/2022 - 10:18 |
Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma |
Johnson and Johnson |
|
Mon, 11/21/2022 - 11:44 |
U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma |
AbbVie |
|
Sun, 11/06/2022 - 15:01 |
Elbit America employees take part in Light The Night in Tarrant County |
Elbit Systems o... |
|
Thu, 11/03/2022 - 10:23 |
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022 |
Gilead Sciences |
|
Tue, 10/11/2022 - 12:20 |
Mayo Clinic Minute: What is CAR-T cell therapy? |
Mayo Clinic |
|
Wed, 09/28/2022 - 07:09 |
CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple Myeloma |
Roswell Park Ca... |
|
Wed, 09/28/2022 - 04:02 |
CAR T-Cell Therapy Targeting GPRC5D Antigen Proves Effective in First Trial in Patients with Resistant Multiple Myeloma |
Dana Farber |
|
Fri, 09/23/2022 - 11:47 |
CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET |
CASI Pharmaceuticals |
|
Tue, 09/20/2022 - 03:29 |
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction |
Celyad |
|
Sun, 08/28/2022 - 20:31 |
Specific Components of the Tumor Immune Microenvironment May Affect the Durability of Responses to BCMA CAR T-cell Therapy |
American Associ... |
|
Wed, 08/24/2022 - 01:48 |
Chugai Obtains Regulatory Approval for POLIVY for Additional Indication of Previously Untreated Diffuse Large B-cell Lymphoma |
Chugai |
|
Wed, 07/27/2022 - 06:04 |
Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma |
Soligenix |
|
Thu, 07/14/2022 - 10:37 |
Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma |
Mayo Clinic |
